ATE273708T1 - Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt - Google Patents
Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermitteltInfo
- Publication number
- ATE273708T1 ATE273708T1 AT95909122T AT95909122T ATE273708T1 AT E273708 T1 ATE273708 T1 AT E273708T1 AT 95909122 T AT95909122 T AT 95909122T AT 95909122 T AT95909122 T AT 95909122T AT E273708 T1 ATE273708 T1 AT E273708T1
- Authority
- AT
- Austria
- Prior art keywords
- txa2
- prophylaxis
- treatment
- pct
- mediated diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 title abstract 4
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 102000003960 Ligases Human genes 0.000 abstract 3
- 108090000364 Ligases Proteins 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- -1 pyridazinone compound Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Confectionery (AREA)
- Medicines Containing Plant Substances (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2455694 | 1994-02-22 | ||
| PCT/JP1995/000244 WO1995022329A1 (en) | 1994-02-22 | 1995-02-20 | Agent for prophylaxis and treatment of thromboxane a2-mediated diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE273708T1 true ATE273708T1 (de) | 2004-09-15 |
Family
ID=12141437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95909122T ATE273708T1 (de) | 1994-02-22 | 1995-02-20 | Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5798357A (de) |
| EP (1) | EP0744950B1 (de) |
| JP (1) | JP3858279B2 (de) |
| KR (1) | KR100345187B1 (de) |
| CN (1) | CN1084620C (de) |
| AT (1) | ATE273708T1 (de) |
| AU (1) | AU1718395A (de) |
| CA (1) | CA2183234C (de) |
| DE (1) | DE69533392T2 (de) |
| DK (1) | DK0744950T3 (de) |
| ES (1) | ES2222464T3 (de) |
| FI (1) | FI116882B (de) |
| IL (1) | IL112695A (de) |
| NO (1) | NO311490B1 (de) |
| WO (1) | WO1995022329A1 (de) |
| ZA (1) | ZA951470B (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW482675B (en) * | 1997-01-31 | 2002-04-11 | Green Cross Corp | Compositions for oral administration containing pyridazinone compounds technical field of the invention |
| DK1025847T3 (da) * | 1997-08-28 | 2006-02-13 | Nissan Chemical Ind Ltd | Neovaskulariseringspromotorer og neovaskulariseringsforstarkere |
| US6143113A (en) | 1998-03-02 | 2000-11-07 | Le Groupe Recherche I.D. Inc. | Repulpable corrugated boxboard |
| RU2229297C2 (ru) * | 1998-09-01 | 2004-05-27 | Ниссан Кемикал Индастриз, Лтд. | Терапевтический агент для лечения стеноза позвоночного канала |
| CA2353956C (en) * | 1998-12-07 | 2008-10-28 | Nissan Chemical Industries, Ltd. | Remedial agent for erectile dysfunction |
| AU2004308806B9 (en) * | 2003-12-26 | 2010-01-28 | Nissan Chemical Industries, Ltd. | Neutrophilia inhibitor |
| WO2009097406A1 (en) * | 2008-01-29 | 2009-08-06 | Indigo Pharmaceuticals | A method of administering a pde3 inhibitor via titration for the treatment of peripheral arterial disease |
| CN113546049B (zh) * | 2021-04-30 | 2023-03-17 | 贵州汉方药业有限公司 | 一种柔性丸剂药物黏合剂及使用该黏合剂制成的柔性丸剂 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4599336A (en) * | 1983-08-08 | 1986-07-08 | Hoffmann-La Roche Inc. | Derivatives of (E)-3-(4-oxo-4H-quinazolin-3-yl)-2-propenamide |
| EP0142057A3 (de) * | 1983-11-04 | 1988-03-30 | F. Hoffmann-La Roche Ag | Thiazolochinazolin-Derivate, ihre Herstellung und sie enthaltende pharmazeutische Zubereitungen |
| HU198696B (en) * | 1987-01-20 | 1989-11-28 | Nissan Chemical Ind Ltd | Process for producing 3/2h/-pyridazinon derivatives and pharmaceutical compositions containing them as active components |
| JPH02256668A (ja) * | 1988-12-20 | 1990-10-17 | Nissan Chem Ind Ltd | ピリダジノン誘導体 |
| ES2149761T3 (es) * | 1990-04-25 | 2000-11-16 | Nissan Chemical Ind Ltd | Derivado de piridazinona. |
-
1995
- 1995-02-19 IL IL11269595A patent/IL112695A/xx not_active IP Right Cessation
- 1995-02-20 CN CN95191744A patent/CN1084620C/zh not_active Expired - Lifetime
- 1995-02-20 CA CA002183234A patent/CA2183234C/en not_active Expired - Lifetime
- 1995-02-20 AT AT95909122T patent/ATE273708T1/de active
- 1995-02-20 DE DE69533392T patent/DE69533392T2/de not_active Expired - Lifetime
- 1995-02-20 AU AU17183/95A patent/AU1718395A/en not_active Abandoned
- 1995-02-20 EP EP95909122A patent/EP0744950B1/de not_active Expired - Lifetime
- 1995-02-20 WO PCT/JP1995/000244 patent/WO1995022329A1/en not_active Ceased
- 1995-02-20 ES ES95909122T patent/ES2222464T3/es not_active Expired - Lifetime
- 1995-02-20 KR KR1019960704529A patent/KR100345187B1/ko not_active Expired - Lifetime
- 1995-02-20 US US08/687,604 patent/US5798357A/en not_active Expired - Lifetime
- 1995-02-20 DK DK95909122T patent/DK0744950T3/da active
- 1995-02-21 JP JP03230095A patent/JP3858279B2/ja not_active Expired - Fee Related
- 1995-02-22 ZA ZA951470A patent/ZA951470B/xx unknown
-
1996
- 1996-08-20 NO NO19963463A patent/NO311490B1/no not_active IP Right Cessation
- 1996-08-21 FI FI963264A patent/FI116882B/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH07285869A (ja) | 1995-10-31 |
| CA2183234A1 (en) | 1995-08-24 |
| AU1718395A (en) | 1995-09-04 |
| DK0744950T3 (da) | 2004-10-25 |
| US5798357A (en) | 1998-08-25 |
| WO1995022329A1 (en) | 1995-08-24 |
| DE69533392D1 (de) | 2004-09-23 |
| KR100345187B1 (ko) | 2002-12-05 |
| CA2183234C (en) | 2004-05-04 |
| EP0744950A1 (de) | 1996-12-04 |
| NO311490B1 (no) | 2001-12-03 |
| CN1141590A (zh) | 1997-01-29 |
| KR970701048A (ko) | 1997-03-17 |
| NO963463L (no) | 1996-08-20 |
| JP3858279B2 (ja) | 2006-12-13 |
| IL112695A (en) | 1999-04-11 |
| FI963264A7 (fi) | 1996-08-21 |
| FI963264A0 (fi) | 1996-08-21 |
| ES2222464T3 (es) | 2005-02-01 |
| DE69533392T2 (de) | 2005-09-01 |
| IL112695A0 (en) | 1995-05-26 |
| FI116882B (fi) | 2006-03-31 |
| EP0744950B1 (de) | 2004-08-18 |
| CN1084620C (zh) | 2002-05-15 |
| ZA951470B (en) | 1995-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA953469B (en) | New compound | |
| ATE443043T1 (de) | Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer | |
| IL112841A0 (en) | Sulfonamide aspartyl protease inhibitors methods for the preparation thereof and pharmaceutical compositions containing the same | |
| DE59409312D1 (de) | Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten | |
| GR3030354T3 (en) | Substituted arylalkynyl- and heteroarylalkynyl-n-hydroxyurea inhibitors of leukotriene biosynthesis. | |
| GEP20053619B (en) | Pyrazole Derivatives for Treating HIV | |
| MXPA04006553A (es) | Compuesto de 4-oxoquinolina y uso del mismo como inhibidor de integrasa de vih. | |
| BRPI0417345A (pt) | compostos inibidores de quìnase baseados em azola, composições e seus usos | |
| IN2005KO00312A (de) | ||
| DE69533392D1 (de) | Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt | |
| PT838223E (pt) | Inibidor do edema cerebral | |
| DE60318874D1 (en) | Pyrazolderivate | |
| DE69315836D1 (de) | Pyrazolpyridine für die behandlung der anämie | |
| NO975726L (no) | N-Hydroksyurea-derivater som anti-inflammatoriske midler | |
| DK0787491T3 (da) | Middel til forebyggelse og behandling af allergiske sygdomme af type I | |
| DE69400704D1 (de) | N-acylpyrrolidine und arzneimittel zur behandlung oder prophylaxe von mit ckk und gastrin in zusammenhang stehenden krankheiten | |
| AU2003263455A1 (en) | Pyrazole amides for treating hiv infections | |
| DK0632717T3 (da) | Middel til anvendelse som et anti-irritationsmiddel | |
| EP1325918A4 (de) | Herzmuskelzellen-apoptose hemmstoffe und behandlung/vorbeugung von herzkrankheiten | |
| DE60321700D1 (de) | Pyrazolderivate und deren verwendung als therapeutische mittel für durch hiv vermittelte krankheiten | |
| DE69503635D1 (de) | Pyrrolidinderivate zur behandlung von cck und gastrin-abhängigen erkrankungen | |
| UY25369A1 (es) | Procedimiento para preparar inhibidores de proteasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0744950 Country of ref document: EP |